Abstract Details

Title Reduction of Pain-Related Symptoms with Transcranial Magnetic Stimulation Treatment in Depressed Patients

Topic Ethics, Pain and Palliative Care

Presentation(s) P02 - (-)

Poster/Presentation
Number 010

Objective

Background BACKGROUND: Over 75% of patients with depression experience pain-related symptoms that interfere with their daily activities. The presence of comorbid moderate-to-extreme pain contributes significantly to unfavorable outcomes, poor health-related quality of life and increased cost for treatment of major depression.

Design/Methods DESIGN/METHODS: Forty-two US-based clinical TMS practice sites treated 307 outpatients with a primary diagnosis of MDD, and persistent symptoms despite prior antidepressant pharmacotherapy. Treatment parameters were based on individual clinical considerations and on the labeled procedures for use of the NeuroStar TMS Therapy® System. The outcome was defined as the change in the bodily pain scores of the Medical Outcomes Study (MOS) 36-Item Short-Form Health Survey (SF-36) and the pain and discomfort EuroQol 5-Dimension (EQ-5D) ratings from baseline through end of acute treatment and 12-month follow-up.

Results RESULTS: The SF-36 bodily pain scores improved significant following acute TMS treatment; this improvement persisted throughout the 12-month follow-up. The percentage of patients that reported moderate and extreme pain reduced from 49.8% to 40.9% and from 10.7% to 6.3% at the end of acute treatment, respectively. The percentage of patients reporting general pain-related problems significantly reduced from 60.6% at baseline to 47.4% at the end of acute treatment (P=0.0013). In addition, there was a significant correlation between the improvement on the SF-36 bodily pain scores and the ameliorating of depressive symptomatology as measured by the PHQ-9 (rp = -0.3868).

Conclusions CONCLUSIONS: In clinical practice TMS shows statistically significant benefits on patient-reported pain outcomes, and improvement in quality of life. These data show that the effectiveness of TMS in the treatment of depression is not only disease-specific but also associated with a general improvement in pain and well-being that persist beyond the acute treatment.

Authors/Disclosures
David G. Brock, MD PRESENTER	No disclosure on file
	No disclosure on file
Dianalee McKnight, PhD (InVitae)	Dr. McKnight has nothing to disclose.

��ɫ��

��ɫ��